At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4139 Biotechnology
Not Yet Opened 09-16 16:00:00 EDT
83.33
+0.02
+0.03%
High83.88Low82.88Vol956.76M
Open83.31D1 Closing83.31Amplitude1.21%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O16.96BT/O Rate--Tradable Shares0.00
P/B8.002181ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Buildings Represent a Fresh Services Sector Model, Not Conventional Property Ventures
Deep News  ·  11:10
Buildings Represent a Fresh Services Sector Model, Not Conventional Property Ventures
Top Executive Makes a Major Move at Aquestive Therapeutics
TIPRANKS  ·  10:06
Top Executive Makes a Major Move at Aquestive Therapeutics
Natera Executive Chairman Matthew Rabinowitz Disposes of 89,100 Common Shares Worth $30.15 Million
Reuters  ·  09:35
Natera Executive Chairman Matthew Rabinowitz Disposes of 89,100 Common Shares Worth $30.15 Million
Puma Biotechnology Director Alessandra Cesano Disposes of 62,150 Common Shares Worth $566,437.45
Reuters  ·  09:07
Puma Biotechnology Director Alessandra Cesano Disposes of 62,150 Common Shares Worth $566,437.45
INmune Bio Director James Sapirstein Files Initial Beneficial Ownership Statement
Reuters  ·  08:05
INmune Bio Director James Sapirstein Files Initial Beneficial Ownership Statement
First Lithium Minerals Launches New LIFE Financing to Fund Chile and Ontario Exploration
TIPRANKS  ·  07:32
First Lithium Minerals Launches New LIFE Financing to Fund Chile and Ontario Exploration
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Dow Jones  ·  06:34
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Reuters  ·  06:15
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Opaleye Management Reports USD 1.07 Million Alpha Cognition Common Share Purchase
Reuters  ·  05:58
Opaleye Management Reports USD 1.07 Million Alpha Cognition Common Share Purchase
Eterna Therapeutics Updates Investors With New Corporate Materials
TIPRANKS  ·  05:57
Eterna Therapeutics Updates Investors With New Corporate Materials
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Dow Jones  ·  05:55
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Reuters  ·  05:45
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Matinas BioPharma Sets 1-for-15 Reverse Stock Split Effective Sept. 28
Reuters  ·  05:45
Matinas BioPharma Sets 1-for-15 Reverse Stock Split Effective Sept. 28
Longeveron to resume trading at 5:55 pm ET
TIPRANKS  ·  05:40
Longeveron to resume trading at 5:55 pm ET
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
TIPRANKS  ·  05:35
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
Longeveron exploring all options for maximizing shareholder value
TIPRANKS  ·  05:35
Longeveron exploring all options for maximizing shareholder value
Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  05:27
Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months
THOMSON REUTERS  ·  05:27
Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months
Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value
THOMSON REUTERS  ·  05:27
Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value
Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty
THOMSON REUTERS  ·  05:27
Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty

Introduction

Company Name.
BK4139
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--